Macro Finance
Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO
Bloomberg Markets·October 30, 2026·1 min read
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% in its US market debut after raising about $140.6 million in an initial public offering. The company, backed by Gilead, focuses on developing treatments for neurological diseases. The modest decline reflects cautious investor sentiment toward biotech IPOs amid market volatility.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.